Clinical Trial Update: A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder [Phase 2]

View source ↗

Summary

Phase II clinical trial update evaluating the efficacy and safety of TQC3721 inhalation powder for chronic obstructive pulmonary disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• TQC3721

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: ACTIVE_NOT_RECRUITING